Bertran-Alamillo et al. revealed that AURKB is related to acquired resistance to EGFR TKIs, and AURKB can become a potential biological target for anti-EGFR therapy of NSCLC without carrying resistance mutations 46. This evidence concerns the gene EGFR and non-small cell lung carcinoma.